Diabetes Clinical Trials in Seattle

Showing 321-340 of 375 trials

Vitamin D and Adipose Tissue Inflammation

NCT01477034

Chronic, low-grade adipose tissue inflammation is a major risk factor for type 2 diabetes mellitus. The cause of adipose tissue inflammation has remained largely unclear. We hypothesize that vitamin D deficiency predisposes individuals to the development of adipose tissue inflammation, and that treatment of vitamin D deficient subjects with high dose vitamin D will reduce adipose tissue inflammation.

Vitamin D DeficiencyObesityType 2 Diabetes Mellitus+1 more

Fred Hutchinson Cancer Center18 participantsStarted Nov 2011

Seattle, Washington, United States

COMPLETEDPhase 2< 1 mile

Iron Depletion Therapy for Type 2 DM and NAFLD

NCT00230087

The purpose of this study is to find out whether lowering the amount of iron in the body will result in less resistance to insulin and improved liver function in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. This may result in better diabetes control and/or a decrease in the amount of liver fat.

Non-Alcoholic Fatty Liver DiseaseDiabetes Mellitus

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)15 participantsStarted Sep 2005

Seattle, Washington, United States

COMPLETEDPhase 26.1 miles

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT00901979

This study will assess the effect of LCQ when added to metformin.

Type 2 Diabetes Mellitus

Novartis Pharmaceuticals693 participantsStarted Apr 2009

Mesa, Arizona, United States • Mesa, Arizona, United States • Little Rock, Arkansas, United States +64 more locations

Vitamin D and Adipose Tissue Inflammation

Iron Depletion Therapy for Type 2 DM and NAFLD

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

Diabetes Trials in Other Cities

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Follow-Up Study for Exubera

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Testing the Developmental Origins Hypothesis

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Other Conditions in Seattle